Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal
connective tissue growth of the skin and internal organs. At this point, there are no
effective therapies for treating SSc. Thalidomide is a medication that has been shown to
stimulate an immune response that reduces the body's synthesis of collagen, the main
component of connective tissue. This study will determine the effectiveness of thalidomide in
treating adults with SSc.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)